The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Glycosylated Proteins Biosimilar Market Research Report 2025
Synopsis
Global Recombinant Glycosylated Proteins Biosimilar market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Glycosylated Proteins Biosimilar market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Glycosylated Proteins Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer, Inc.
Intas Pharmaceuticals Ltd.
Biocon
Dr. Reddy’s Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Sandoz International GmbH (A Novartis Division)
Celltrion Inc.
Amgen, Inc.
STADA Arzneimittel AG
Apotex Inc.
Segment by Type
Monoclonal Antibodies
Erythropoietin
Others
Segment by Application
Chronic Diseases
Oncology
Autoimmune Diseases
Infectious Diseases
Blood Disorders
Growth Hormone Deficiency
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Glycosylated Proteins Biosimilar report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Global Recombinant Glycosylated Proteins Biosimilar market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Glycosylated Proteins Biosimilar market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Glycosylated Proteins Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer, Inc.
Intas Pharmaceuticals Ltd.
Biocon
Dr. Reddy’s Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Sandoz International GmbH (A Novartis Division)
Celltrion Inc.
Amgen, Inc.
STADA Arzneimittel AG
Apotex Inc.
Segment by Type
Monoclonal Antibodies
Erythropoietin
Others
Segment by Application
Chronic Diseases
Oncology
Autoimmune Diseases
Infectious Diseases
Blood Disorders
Growth Hormone Deficiency
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Glycosylated Proteins Biosimilar report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Recombinant Glycosylated Proteins Biosimilar Market Overview
1.1 Product Overview and Scope of Recombinant Glycosylated Proteins Biosimilar
1.2 Recombinant Glycosylated Proteins Biosimilar Segment by Type
1.2.1 Global Recombinant Glycosylated Proteins Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Monoclonal Antibodies
1.2.3 Erythropoietin
1.2.4 Others
1.3 Recombinant Glycosylated Proteins Biosimilar Segment by Application
1.3.1 Global Recombinant Glycosylated Proteins Biosimilar Market Value by Application: (2023-2029)
1.3.2 Chronic Diseases
1.3.3 Oncology
1.3.4 Autoimmune Diseases
1.3.5 Infectious Diseases
1.3.6 Blood Disorders
1.3.7 Growth Hormone Deficiency
1.3.8 Others
1.4 Global Recombinant Glycosylated Proteins Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Recombinant Glycosylated Proteins Biosimilar Revenue 2018-2029
1.4.2 Global Recombinant Glycosylated Proteins Biosimilar Sales 2018-2029
1.4.3 Global Recombinant Glycosylated Proteins Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Glycosylated Proteins Biosimilar Market Competition by Manufacturers
2.1 Global Recombinant Glycosylated Proteins Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Glycosylated Proteins Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Glycosylated Proteins Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Glycosylated Proteins Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Glycosylated Proteins Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Glycosylated Proteins Biosimilar, Product Type & Application
2.7 Recombinant Glycosylated Proteins Biosimilar Market Competitive Situation and Trends
2.7.1 Recombinant Glycosylated Proteins Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Glycosylated Proteins Biosimilar Players Market Share by Revenue
2.7.3 Global Recombinant Glycosylated Proteins Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Glycosylated Proteins Biosimilar Retrospective Market Scenario by Region
3.1 Global Recombinant Glycosylated Proteins Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Glycosylated Proteins Biosimilar Global Recombinant Glycosylated Proteins Biosimilar Sales by Region: 2018-2029
3.2.1 Global Recombinant Glycosylated Proteins Biosimilar Sales by Region: 2018-2023
3.2.2 Global Recombinant Glycosylated Proteins Biosimilar Sales by Region: 2024-2029
3.3 Global Recombinant Glycosylated Proteins Biosimilar Global Recombinant Glycosylated Proteins Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Recombinant Glycosylated Proteins Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Recombinant Glycosylated Proteins Biosimilar Revenue by Region: 2024-2029
3.4 North America Recombinant Glycosylated Proteins Biosimilar Market Facts & Figures by Country
3.4.1 North America Recombinant Glycosylated Proteins Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Glycosylated Proteins Biosimilar Sales by Country (2018-2029)
3.4.3 North America Recombinant Glycosylated Proteins Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Glycosylated Proteins Biosimilar Market Facts & Figures by Country
3.5.1 Europe Recombinant Glycosylated Proteins Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Glycosylated Proteins Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Recombinant Glycosylated Proteins Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Glycosylated Proteins Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Glycosylated Proteins Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Glycosylated Proteins Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Glycosylated Proteins Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Glycosylated Proteins Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Recombinant Glycosylated Proteins Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Glycosylated Proteins Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Glycosylated Proteins Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Glycosylated Proteins Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Glycosylated Proteins Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Glycosylated Proteins Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Glycosylated Proteins Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Glycosylated Proteins Biosimilar Sales by Type (2018-2029)
4.1.1 Global Recombinant Glycosylated Proteins Biosimilar Sales by Type (2018-2023)
4.1.2 Global Recombinant Glycosylated Proteins Biosimilar Sales by Type (2024-2029)
4.1.3 Global Recombinant Glycosylated Proteins Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Glycosylated Proteins Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Recombinant Glycosylated Proteins Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Recombinant Glycosylated Proteins Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Recombinant Glycosylated Proteins Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Glycosylated Proteins Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Glycosylated Proteins Biosimilar Sales by Application (2018-2029)
5.1.1 Global Recombinant Glycosylated Proteins Biosimilar Sales by Application (2018-2023)
5.1.2 Global Recombinant Glycosylated Proteins Biosimilar Sales by Application (2024-2029)
5.1.3 Global Recombinant Glycosylated Proteins Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Glycosylated Proteins Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Recombinant Glycosylated Proteins Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Recombinant Glycosylated Proteins Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Recombinant Glycosylated Proteins Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Glycosylated Proteins Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer, Inc.
6.1.1 Pfizer, Inc. Corporation Information
6.1.2 Pfizer, Inc. Description and Business Overview
6.1.3 Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.1.5 Pfizer, Inc. Recent Developments/Updates
6.2 Intas Pharmaceuticals Ltd.
6.2.1 Intas Pharmaceuticals Ltd. Corporation Information
6.2.2 Intas Pharmaceuticals Ltd. Description and Business Overview
6.2.3 Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.2.5 Intas Pharmaceuticals Ltd. Recent Developments/Updates
6.3 Biocon
6.3.1 Biocon Corporation Information
6.3.2 Biocon Description and Business Overview
6.3.3 Biocon Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biocon Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.3.5 Biocon Recent Developments/Updates
6.4 Dr. Reddy’s Laboratories Ltd.
6.4.1 Dr. Reddy’s Laboratories Ltd. Corporation Information
6.4.2 Dr. Reddy’s Laboratories Ltd. Description and Business Overview
6.4.3 Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.4.5 Dr. Reddy’s Laboratories Ltd. Recent Developments/Updates
6.5 Teva Pharmaceutical Industries Ltd.
6.5.1 Teva Pharmaceutical Industries Ltd. Corporation Information
6.5.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.5.3 Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.6 Sandoz International GmbH (A Novartis Division)
6.6.1 Sandoz International GmbH (A Novartis Division) Corporation Information
6.6.2 Sandoz International GmbH (A Novartis Division) Description and Business Overview
6.6.3 Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.6.5 Sandoz International GmbH (A Novartis Division) Recent Developments/Updates
6.7 Celltrion Inc.
6.6.1 Celltrion Inc. Corporation Information
6.6.2 Celltrion Inc. Description and Business Overview
6.6.3 Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.7.5 Celltrion Inc. Recent Developments/Updates
6.8 Amgen, Inc.
6.8.1 Amgen, Inc. Corporation Information
6.8.2 Amgen, Inc. Description and Business Overview
6.8.3 Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.8.5 Amgen, Inc. Recent Developments/Updates
6.9 STADA Arzneimittel AG
6.9.1 STADA Arzneimittel AG Corporation Information
6.9.2 STADA Arzneimittel AG Description and Business Overview
6.9.3 STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.9.4 STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.9.5 STADA Arzneimittel AG Recent Developments/Updates
6.10 Apotex Inc.
6.10.1 Apotex Inc. Corporation Information
6.10.2 Apotex Inc. Description and Business Overview
6.10.3 Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Product Portfolio
6.10.5 Apotex Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Glycosylated Proteins Biosimilar Industry Chain Analysis
7.2 Recombinant Glycosylated Proteins Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Glycosylated Proteins Biosimilar Production Mode & Process
7.4 Recombinant Glycosylated Proteins Biosimilar Sales and Marketing
7.4.1 Recombinant Glycosylated Proteins Biosimilar Sales Channels
7.4.2 Recombinant Glycosylated Proteins Biosimilar Distributors
7.5 Recombinant Glycosylated Proteins Biosimilar Customers
8 Recombinant Glycosylated Proteins Biosimilar Market Dynamics
8.1 Recombinant Glycosylated Proteins Biosimilar Industry Trends
8.2 Recombinant Glycosylated Proteins Biosimilar Market Drivers
8.3 Recombinant Glycosylated Proteins Biosimilar Market Challenges
8.4 Recombinant Glycosylated Proteins Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
